following a full submission:
dasatinib (Sprycel®) is accepted for use within NHS Scotland.
Indication under review: for the treatment of adult patients with newly diagnosed Philadelphia chromosome positive (Ph+) chronic myelogenous leukaemia (CML) in the chronic phase.
In an open-label, phase III study, dasatinib was associated with significantly higher cytogenetic and molecular response rates at 12 months compared with another tyrosine kinase inhibitor. There were no differences in progression-free or overall survival.
This SMC advice takes account of the benefits of a Patient Access Scheme (PAS) that improves the cost-effectiveness of dasatinib. This advice is contingent upon the continuing availability of the PAS in NHS Scotland or a list price that is equivalent or lower.
Download detailed advice263KB (PDF)
Medicine details
- Medicine name:
- dasatinib (Sprycel)
- SMC ID:
- 1170/16
- Indication:
- For the treatment of adult patients with newly diagnosed Philadelphia chromosome positive (Ph+) chronic myelogenous leukaemia (CML) in the chronic phase.
- Pharmaceutical company
- Bristol-Myers Squibb Pharmaceuticals Ltd
- BNF chapter
- Malignant disease and immunosuppression
- Submission type
- Full
- Status
- Accepted
- Date advice published
- 12 September 2016